CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cytosorbents (CTSO) Reports FY18 Loss of $0.56
March 7, 2019 4:22 PM ESTCytosorbents (NASDAQ: CTSO) reported Q4 FY18 of ($0.56), versus ($0.32) reported last year. Revenue for the year came in at $22.5 million, versus $15.15 million reported last year.
For earnings history and earnings-related data on Cytosorbents (CTSO) click here.
... More